Compugen Ltd. - Ordinary Shares (CGEN)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 4, 2026Investment Snapshot
- Trading 10% below Graham Number — thin margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 34.4% with 48.6% net margin
- Revenue growing at 161% annually
Compugen Ltd. - Ordinary Shares (CGEN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $256 million . Key value metrics: P/E ratio 7.3, P/B ratio 2.49, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Compugen Ltd. - Ordinary Shares — Fundamental Analysis Summary
Compugen Ltd. - Ordinary Shares (CGEN) is trading 10% below its Graham Number of $3.02, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 7.3x.
On financial health, CGEN shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 34.4% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for CGEN is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CGEN reports a high gross margin of 87.3% (sector average: 40.1%) and a strong operating margin of 43.1%.
CGEN shows revenue growing at 161% year-over-year, with earnings growing at 348%.